|
Datasets with Melanoma |
The duplicated datasets indicate that this dataset include both pre-treatment and post-treatment samples, and partial analyses were conducted on each of the two timepoints. The dataset page shows more informations, and the analysis results of this dataset. |
Dataset | Source | Tissue | Cancer type level1 | Cancer type level2 | Drug type | Regimen | Timepoint |
GSE164237 | patients | Peripheral blood mononuclear cells | Melanoma | Advanced stages of melanoma | Immunotherapy | pembrolizumab | post |
GSE164237 | patients | Peripheral blood mononuclear cells | Melanoma | Advanced stages of melanoma | Immunotherapy | pembrolizumab | pre |
GSE108397 | 451Lu cell line | Cell line | Melanoma | Melanoma | Targeted therapy | PLX-4720 | NA |
GSE164897_VemTra | A375 cell line | Cell line | Melanoma | B+E2:E57RAFV600E-mutant melanoma | Targeted therapy | vemurafenib + trametinib | NA |
GSE164897_VemCob | A375 cell line | Cell line | Melanoma | BRAFV600E-mutant melanoma | Targeted therapy | vemurafenib + combimetinib | NA |